Media
-
Racura Oncology Presents Key MYC Silencing Data at Major Cancer Conference
ShareCafe: Racura Oncology Ltd (ASX: RAC) has announced the presentation of significant mechanism of action data concerning its lead asset, (E,E)-bisantrene, at the prestigious 2026 American Association of Cancer Research (AACR) Annual Meeting. Read the article here.
-
Long Shortz with Racura: Tackling MYC-driven cancer pathways
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) Executive Chair Dr Pete Smith to discuss the company’s HARNESS-1 lung cancer trial. Watch the video here
-
Racura teams with Purdue Uni to advance cancer drug candidate
Racura and Purdue University in US partner for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure. Read the full article here.
-
Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett to discuss the company’s upcoming HARNESS-1 lung cancer trial. Watch the video here.
-
Pioneering Aussie biotechs pass the clinical test
The performance of the ASX life sciences sector during the reporting season is a precautionary tale about not trusting statistics – or at least not relying on them at face value. Read article here
-
Racura scientists develop cardioprotection blood test to support key trial
Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220. Read article here.
-
Long Shortz with Racura: Unlocking major IP and clinical milestones in transformative quarter
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones. Watch the interview here.
-
Proactive Investors: Race Oncology funds HARNESS-1 lung cancer trial
Race Oncology Ltd executive director and chairman Dr Peter Smith talked with Proactive about securing more than A$3.22 million via a private placement to fund the HARNESS-1 Phase 1a/b clinical trial. Read full article here.
-
Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Special Report: Racura Oncology has taken a significant step forward in the clinical development of its next-generation cancer therapy RC220, receiving human ethics approval for a HARNESS-1 Phase 1a/b trial in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Read full article here.
